Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 29/11/2020
SIETES contiene 93175 citas

 1 a 20 de 34 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Kearon C, Spencer FA, O'Keeffe D, Parpia S, Schulman S, Baglin T, Stevens SM, Kaatz S, Bauer KA, Douketis JD, Lentz SR, Kessler CM, Moll S, Connors JM, Ginsberg JS, Spadafora L, Julian JA, for the d-Dimer Optimal Duration Study Investigators. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med 2015;162:27-34. [Ref.ID 98754]
2. Cita con resumen
Linkins L-A, Bates SM, Lang E, Kahn SR, Doukelis JD, Julian J, Parpia S, Gross P, Weltz JI, Spencer FA, Lee AYY, O'Donnell MJ, Crowther MA, Chan HH, Lim W, Schulman S, Ginsberg JS, Kearon C. Selective D-dimer testing for diagnosis of a first suspected episode of deep venous thrombosis: a randomized trial. Ann Intern Med 2013;158:93-100. [Ref.ID 94774]
Khan SR, Shrier I, Julian JA, Ducruet T, Arsenault L, Miron M-J, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Lamping DL, Johri M, Ginsberg JS. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med 2008;149:698-707. [Ref.ID 84608]
4.Tiene citas relacionadas Cita con resumen
Eikelboom JW, Ginsberg JS, Hirsh J. Anticoagulation for venous thromboembolism. BMJ 2007;334:645. [Ref.ID 79696]
5.Tiene citas relacionadas
Kearon C, Ginsberg JS, Julian JA, Gent M. Fixed-dose unfractionated heparin vs low-molecular-weight heparin for venous thromboembolism. JAMA 2007;297:262-3. [Ref.ID 78925]
6.Tiene citas relacionadas Cita con resumen
Kearon C, Ginsberg JS, Julian JA, Douketis J, Solymoss S, Ockelford P, Jackson S, Turpie AG, MacKinnon B, Hirsh J, Gent M, for the Fixed-Dose Heparin (FIDO) Investigators. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 2006;296:935-42. [Ref.ID 77931]
7.Tiene citas relacionadas Cita con resumen
Fiessinger JN, Huisman MV, Davidson BL, Bounameux H, Francis CW, Eriksson H, Lundström T, Berkowitz SD, Nyström P, Thorsén M, Ginsberg JS, for the THRIVE Treatment Study Investigators. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis. A randomized trial. JAMA 2005;293:681-9. [Ref.ID 72737]
8.Tiene citas relacionadas
Ginsberg JS. Routine stocking therapy after deep venous thrombosis: a clinical dilemma. Ann Intern Med 2004;141:314-5. [Ref.ID 71133]
9.Tiene citas relacionadas
Bates SM, Ginsberg JS. Treatment of deep-vein thrombosis. N Engl J Med 2004;351:268-77. [Ref.ID 70768]
10. Cita con resumen
Chan WS, Ray J, Wai EK, Ginsburg S, Hannah ME, Corey PN, Ginsberg JS. Risk of stroke in women exposed to low-dose oral contraceptives. Arch Intern Med 2004;164:741-7. [Ref.ID 69820]
11.Tiene citas relacionadas
Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, Peters G R, Roth A W, McElhattan J, Colwell CW, for the EXULT A Study Group. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003;349:1703-12. [Ref.ID 67973]
Crowter MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura W, Wilson S, Gent M, Kovacs MJ. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003;121:1133-8. [Ref.ID 67398]
13.Tiene citas relacionadas
Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Math JAJM, MacKinnon B, Weitz JI, Crowther MA, Dolan S, Turpie AG, Geerts W, Solymoss S, van Nguyen P, Demers C, Kahn SR, Kassis J, Rodger M, Hambleton J, Gent M, for the Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003;349:631-9. [Ref.ID 67107]
Ginsberg JS, Chan WS, Bates SM, Kaatz S. Anticoagulation of pregnant women with mechanical heart valves. Arch Intern Med 2003;163:694-8. [Ref.ID 65493]
15. Cita con resumen
Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Ginsberg JS, Lieberman JR, Webster AK, Whipple JP, Peters G R, Colwell CW. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double blind trial. Ann Intern Med 2002;137:648-55. [Ref.ID 63669]
16. Cita con resumen
Heit JA, Colwell CW, Francis CW, Ginsberg JS, Berkowitz SD, Whipple J, Peters G, for the AstraZeneca Arthroplasty Study Group. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement. Arch Intern Med 2001;161:2215-21. [Ref.ID 58993]
Ginsberg JS, Hirsh J, Julian J, LaandeVries MV, Magier D, MacKinnon B, Gent M. Prevention and treatment of postphlebitic syndrome. Results of a 3-part study. Arch Intern Med 2001;161:2105-9. [Ref.ID 58626]
18. Cita con resumen
Attia J, Ray J G, Cook DJ, Douketis J, Ginsberg JS, Geerts WH. Deep vein thrombosis and its prevention in critically ill adults. Arch Intern Med 2001;161:1268-79. [Ref.ID 56980]
19. Cita con resumen
Brill-Edwards P, Ginsberg JS, Gent M, Hirsh J, Brurrows R, Kearon C, Geerts W, Kovacs M, Weitz JI, Robinson S, Whittom R, Couture G, for the Recurrence of Clot in This Pregnancy Study Group. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. N Engl J Med 2000;343:1439-44. [Ref.ID 53963]
20.Tiene citas relacionadas Cita con resumen
Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000;355:1936-42. [Ref.ID 51223]
Seleccionar todas
 1 a 20 de 34 siguiente >>